Summary
Regeneron Pharmaceuticals, Inc. reported solid financial results for the first quarter of 2017, demonstrating robust revenue growth and improved profitability compared to the same period in the prior year. Total revenues increased by approximately 10% year-over-year, driven by strong net product sales, primarily from EYLEA, and growth in collaboration revenues. Net income saw a significant increase, reflecting improved operational efficiency and strong top-line performance. The company's balance sheet remains healthy, with a substantial increase in cash and cash equivalents and a solid working capital position, providing financial flexibility for ongoing research and development activities and strategic investments. The company's pipeline continues to advance, with key product candidates progressing through clinical trials. Significant regulatory milestones were achieved with the U.S. FDA approval of Dupixent for atopic dermatitis and Health Canada approval for Kevzara for rheumatoid arthritis. These advancements, coupled with the continued success of EYLEA and growing contributions from other collaborations, position Regeneron favorably for future growth. Investors should monitor ongoing patent litigation related to Praluent and regulatory developments for key pipeline assets.
Financial Highlights
46 data points| Revenue | $1.32B |
| Cost of Revenue | $61.25M |
| Gross Profit | $1.26B |
| R&D Expenses | $507.44M |
| SG&A Expenses | $296.85M |
| Operating Expenses | $888.45M |
| Operating Income | $430.54M |
| Interest Expense | $7.50M |
| Net Income | $248.90M |
| EPS (Basic) | $2.36 |
| EPS (Diluted) | $2.16 |
| Shares Outstanding (Basic) | 105.57M |
| Shares Outstanding (Diluted) | 115.11M |
Key Highlights
- 1Total revenues increased to $1.319 billion in Q1 2017 from $1.201 billion in Q1 2016, a rise of approximately 10%.
- 2Net income grew to $248.9 million in Q1 2017, or $2.16 per diluted share, compared to $181.4 million, or $1.59 per diluted share, in Q1 2016.
- 3EYLEA net product sales in the U.S. increased to $854.4 million from $780.9 million year-over-year.
- 4The company ended the quarter with $811.8 million in cash and cash equivalents, a significant increase from $535.2 million at the end of 2016.
- 5Significant progress was made with regulatory approvals: Dupixent received FDA approval for atopic dermatitis in March 2017, and Kevzara received Health Canada approval for rheumatoid arthritis in January 2017.
- 6Research and development expenses increased to $507.4 million from $470.1 million year-over-year, reflecting continued investment in pipeline development.
- 7The company is involved in ongoing patent litigation concerning Praluent, with an appeal scheduled for oral argument in June 2017, which could impact future commercial availability.